About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Nebraska Medicine Hematology/Oncology
www.nebraskamed.com
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Hematology Highlights: A Post ASH Review
Leukemia Symposium: Focus on Opportunities to Improve Care
2018 Pan Pacific Lymphoma Conference
Bench to Bedside
Novel Therapies in Lymphoma
High Grade B-cell Lymphoma
Aggressive T-Cell Lymphoma
Hodgkin Lymphoma
Multiple Myeloma/Plasma Cell Dyscrasia
Common Indolent Lymphoma
Uncommon Indolent Lymphoma
Interprofessional Educational Day
13th Annual Fall Midwest Thoracic and GI Oncology Conference
GI
Lung
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therapy for NDMM & Cost and Quality of Anti-Resorptive Agents
By
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
FEATURING
Ashley Rosko
By
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
FEATURING
Ashley Rosko
216 views
March 9, 2020
0 Comments
Login to view comments.
Click here to Login
Featured Video
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
Hematology Highlights: A Post ASH Review
15:04
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
New Therapies in AML: Is It Safe to Wait for Genomic Info to Start T…
Feat.
E. Wang
13:32
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
AML Treatment Options: Modulating p53 Pathways, Targeting FLT3 Inhib…
Feat.
E. Wang
10:46
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Harnessing the Immune System - Immunotherapy for AML, Targeting Anti…
Feat.
E. Wang
18:28
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Malignancy-Associated Thrombosis: DOACs in Treatment of Cancer-Assoc…
Feat.
B. McMahon
14:19
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombos…
Feat.
B. McMahon
10:47
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Updates in Indolent NHL: EZH2 Inhibition & Lenalidomide…
Feat.
N. Fowler
11:25
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Updates in Aggressive NHL: Liso-cel in R/R DLBCL, CD19 Loss…
Feat.
N. Fowler
08:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
CAR T-cell for MCL, LOXO-305 Effective in Pretreated B-Cell, Nivo an…
Feat.
N. Fowler
11:56
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Myeloma Highlights: Genetic Engineering of T-cells, Dara-VM…
Feat.
A. Rosko
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Th…
Feat.
A. Rosko
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Respons…
Feat.
A. Rosko
17:27
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
CLL Therapy in 2020 - Ibrutinib+ Rituximab Provides Superior PFS and…
Feat.
R. Bociek
15:39
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
CLL Highlights from ASH: Chemo Free Therapy Achieves MRD Clearance, …
Feat.
R. Bociek
09:52
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Impact of Next Generation Sequencing on MDS, Scoring System & Cl…
Feat.
H. Carraway
17:41
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Treatment of 62 y/o Man With Low Risk MDS With Anemia: Data on Lenal…
Feat.
H. Carraway
13:11
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Emerging Therapies in MDS: Novel Oral HMT May Become Basis of New Ba…
Feat.
H. Carraway
13:21
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 AML Update: Is It Safe to Wait for Genomic Info to Start Th…
Feat.
E. Wang
12:03
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 AML Update: Ven-based Therapy Can Provide a Path to AlloSCT…
Feat.
E. Wang
08:48
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 ALL Update: Reduced-intensity Chemo Shows Encouraging Resul…
Feat.
E. Wang
13:02
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Current Treatment Algorithm & Disease Complications in ET, PV, M…
Feat.
A. Tefferi
17:47
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Update in MPN: Triple Negative ET, Ropeginterferon in PV &a…
Feat.
A. Tefferi
